Idiopathic Pulmonary Fibrosis

A Global Strategic Business Report

MCP12522

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

5558

EXECUTIVE POOL

5850

PRICE

889

EXPERT INPUTS

16

COMPANIES

123

DATA TABLES

181

PAGES

5

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (19563)

674

CXO

885

VICE PRESIDENT

7666

DIRECTOR

8773

MANAGER

1565

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Idiopathic Pulmonary Fibrosis Market to Reach US$6.8 Billion by 2030

The global market for Idiopathic Pulmonary Fibrosis estimated at US$4.9 Billion in the year 2024, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PIRFENIDONE, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the NINTEDANIB segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.4% CAGR

The Idiopathic Pulmonary Fibrosis market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Idiopathic Pulmonary Fibrosis Market - Key Trends and Drivers Summarized

What Is Idiopathic Pulmonary Fibrosis and Why Should It Matter?

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressively debilitating lung disease that primarily affects the tissues in and around the air sacs of the lungs. The exact cause of IPF is unknown, hence the term "idiopathic," but it leads to scarring (fibrosis) of the lung tissue, making it increasingly difficult for the lungs to carry out their vital function of oxygen exchange. Over time, this scarring becomes more pronounced, causing the lungs to become stiff, and patients experience severe shortness of breath, fatigue, and a persistent dry cough. IPF typically affects adults aged 50 to 70 years, and the disease tends to worsen over time, with a median survival of about three to five years after diagnosis. Although IPF is not as common as other respiratory diseases, it remains a significant concern due to its poor prognosis and lack of a definitive cure, making it a crucial area of study in respiratory medicine.

How Is Idiopathic Pulmonary Fibrosis Diagnosed and Treated?

Diagnosing IPF can be complex, often involving a combination of imaging techniques, lung function tests, and sometimes even lung biopsies. High-resolution CT (HRCT) scans are commonly used to identify the characteristic scarring pattern in the lungs, known as usual interstitial pneumonia (UIP). A thorough clinical evaluation, including ruling out other potential causes of pulmonary fibrosis, is crucial. Despite advancements in diagnostic techniques, IPF remains difficult to distinguish from other interstitial lung diseases (ILDs), contributing to delays in diagnosis and treatment. When it comes to treatment, there are no therapies that can reverse the damage caused by the disease. However, antifibrotic medications such as pirfenidone and nintedanib have been shown to slow down the progression of the disease by reducing lung function decline. These drugs are now considered the standard of care for IPF patients, although they do not offer a cure. Oxygen therapy, pulmonary rehabilitation, and, in severe cases, lung transplantation are additional treatment options that may improve the quality of life for those suffering from IPF.

What Are the Current Trends in IPF Research and Technological Advancements?

IPF research is evolving rapidly as the scientific community continues to explore new pathways and therapeutic targets to improve patient outcomes. Several investigational drugs are in various stages of clinical trials, focusing on molecular mechanisms such as fibroblast activation, inflammation, and oxidative stress, which contribute to lung fibrosis. Biomarkers, which can help in early detection and prognosis, are also a growing area of interest, with the hope that they will aid in identifying high-risk individuals and personalizing treatment approaches. Advances in gene therapy and regenerative medicine are being explored as potential ways to halt or even reverse the fibrotic process. Additionally, patient-centric approaches, such as telemedicine and wearable technologies, are being incorporated into disease management, allowing for real-time monitoring of symptoms and lung function. These innovations could revolutionize the way IPF is diagnosed and managed, providing hope for more personalized and effective interventions.

What Is Driving the Growth in the IPF Market?

The growth in the idiopathic pulmonary fibrosis market is driven by several factors, primarily technological advancements, increasing awareness of the disease, and an aging population. On the technological front, the development of novel diagnostic tools, such as AI-enhanced imaging systems and biomarker-based tests, is making early and accurate diagnosis more feasible. These innovations are helping to address the challenge of late diagnosis, which has historically plagued IPF treatment. Another significant driver is the increasing prevalence of IPF among older adults, particularly as life expectancy continues to rise globally. The growing number of clinical trials for new drug therapies is also propelling the market, with pharmaceutical companies investing heavily in the research and development of antifibrotic agents and other treatments. Patient behavior is shifting too, with more individuals seeking specialized care and participating in clinical studies, driven by greater awareness of the disease and the availability of treatment options. Additionally, the expansion of healthcare infrastructure in emerging markets is broadening access to IPF therapies, further fueling market growth. Together, these factors are shaping a more dynamic and rapidly expanding landscape for IPF research and treatment.

SCOPE OF STUDY

The report analyzes the Idiopathic Pulmonary Fibrosis market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Pirfenidone, Nintedanib); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Providers).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Biogen, Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cipla Ltd.; F. Hoffmann-La Roche AG; FibroGen, Inc.; Galapagos NV; MediciNova, Inc.; Merck & Co., Inc.; Promedior, Inc.; ProMetic Life Sciences, Inc.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Tariff Impact on Global Supply Chain Patterns

Global Economic Update

Idiopathic Pulmonary Fibrosis – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 16 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of Lung Diseases Drives Growth in Idiopathic Pulmonary Fibrosis Treatment Market

Role of Anti-fibrotic Drugs in Improving Patient Outcomes Strengthens Business Case for Adoption

Increasing Focus on Early Diagnosis and Treatment of IPF Fuels Market Demand

Growth in Use of Combination Therapies and Biologics Expands Market Opportunities for IPF Treatment

Growth in Demand for IPF Therapies in Aging Populations Fuels Market Expansion

Increasing Focus on Targeted Therapy and Immunotherapy for IPF Expands Addressable Market

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for PIRFENIDONE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for NINTEDANIB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Idiopathic Pulmonary Fibrosis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

JAPAN

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

CHINA

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

EUROPE

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

FRANCE

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

GERMANY

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

UNITED KINGDOM

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Amplia Therapeutics Ltd.	%
Annji Pharmaceutical Co Ltd.	%
ApiFix	%
Aqualung Therapeutics	%
Avalyn Pharma	%
Boehringer Ingelheim International GmbH	%
Bristol-Myers Squibb Company	%
Cipla Ltd.	%
F. Hoffmann-La Roche Ltd.	%
FibroGen, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll